Research Toward a Cure Trials
Ending HIV requires sustained research. TAG’s April 2026 cure trials update tracks clinical studies worldwide, helping advocates, researchers, and communities follow progress toward a cure.
TAG and ANEA Coalition Condemn Proposed $2 Billion in Cuts to HIV Funding
Treatment Action Group and ANEA Coalition strongly condemn the House Labor, Health and Human Services proposed $2 billion in federal cuts to domestic HIV programs, including plans that would dismantle the CDC’s Division of HIV Prevention and slash $535 million from the Ryan White HIV/AIDS Program.
Statement from TAG’s HIV Project on FDA’s Approval of Injectable Pre-Exposure Prophylaxis
Treatment Action Group (TAG) welcomes and celebrates the U.S. Food and Drug Administration’s (FDA) approval of Apretude brand cabotegravir, the first injectable medication for use as pre-exposure prophylaxis (PrEP) to reduce the risk of HIV transmission.
Treatment Action Group Statement on New HIV Remission Case Report at AIDS2020
Yesterday, a widely reported presentation by Ricardo Diaz at the ongoing virtual International AIDS Conference (AIDS2020) disclosed that one out of 30 total participants in an HIV cure-related research trial conducted in Brazil has not experienced an HIV viral load rebound for a little over a year (64.7 weeks) after interrupting antiretroviral therapy (ART).
Cure-Related Research Resources
A resource listing of articles, reports, websites, and ongoing clinical trials related to the research effort to cure HIV infection.
Statement from the ACT NOW:END AIDS Coalition on President Trump’s State of the Union Commitment to Eradicate AIDS
The ACT NOW:END AIDS Coalition, of which TAG is a founding member, released this statement today calling for the administration’s efforts to end the HIV epidemic to be rooted in fact, science, and sensible policies that are consistent with the stated goal of ending HIV.
HIV & Aging
A resource listing of articles, reports, websites, and ongoing clinical trials related to HIV and aging.
Clinical Trials for People with Suboptimal Immune Reconstitution Despite HIV Suppression
Some individuals who initiate antiretroviral therapy (ART) experience limited recovery of CD4 T cell numbers despite suppression of HIV viral load to undetectable levels. The most common risk factors for this type of discordant response to ART are low CD4 T cell count at the time of starting and older age.
TAG Welcomes HHS Lawsuit Against Gilead; Urges Dramatic Scale-Up of Low-Cost PrEP
Treatment Action Group (TAG) welcomes the U.S. Department of Health and Human Services (HHS) pursuit of a lawsuit against Gilead Sciences, Inc., the manufacturer of Truvada and Descovy, the only two FDA-approved pills for pre-exposure prophlyaxis (PrEP) to prevent HIV.